D. E. Shaw & Co. Inc. Buys New Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

D. E. Shaw & Co. Inc. bought a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 157,352 shares of the company's stock, valued at approximately $6,507,000. D. E. Shaw & Co. Inc. owned about 0.33% of Mirum Pharmaceuticals as of its most recent filing with the SEC.

Several other hedge funds also recently bought and sold shares of the company. Barclays PLC raised its stake in Mirum Pharmaceuticals by 4.6% during the 3rd quarter. Barclays PLC now owns 245,918 shares of the company's stock valued at $9,592,000 after purchasing an additional 10,824 shares during the period. Hennion & Walsh Asset Management Inc. raised its holdings in shares of Mirum Pharmaceuticals by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company's stock worth $6,021,000 after acquiring an additional 29,545 shares in the last quarter. Avanza Fonder AB purchased a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth $189,000. Secure Asset Management LLC increased its holdings in shares of Mirum Pharmaceuticals by 9.3% in the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company's stock worth $1,651,000 after buying an additional 3,406 shares during the last quarter. Finally, R Squared Ltd purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $69,000.

Insider Buying and Selling

In other news, CEO Christopher Peetz sold 27,279 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $44.21, for a total value of $1,206,004.59. Following the completion of the sale, the chief executive officer now owns 138,641 shares in the company, valued at approximately $6,129,318.61. The trade was a 16.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Patrick J. Heron acquired 1,335 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, March 4th. The stock was acquired at an average cost of $45.57 per share, with a total value of $60,835.95. Following the purchase, the director now directly owns 163,643 shares of the company's stock, valued at $7,457,211.51. This represents a 0.82% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 92,764 shares of company stock valued at $4,109,161 over the last quarter. 14.36% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Trading Down 2.0%

Shares of NASDAQ MIRM traded down $0.93 during mid-day trading on Wednesday, reaching $44.42. The company had a trading volume of 42,027 shares, compared to its average volume of 522,428. The business's 50-day moving average is $42.97 and its 200-day moving average is $44.55. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -21.99 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.83 and a 52 week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. The company had revenue of $111.59 million during the quarter, compared to analysts' expectations of $98.47 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm's quarterly revenue was up 61.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.54) EPS. Equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $73.00 price target on shares of Mirum Pharmaceuticals in a report on Monday. JMP Securities lifted their price objective on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research note on Friday, May 9th. Finally, Raymond James reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $60.73.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.